Interní Med. 2007; 9(2): 75-77

TREATMENT OF ARTERIAL HYPERTENSION IN THE ELDERLY

MUDr. Jitka Seidlerová, doc. MUDr. Jan Filipovský CSc
II. interní klinika LF UK a FN, Plzeň

Arterial hypertension is one of most common health problems in the elderly and at the same time is one of the main cardiovascular risk factors. Isolated systolic hypertension with a widened pulse pressure is the most common type of hypertension seen in persons older 65 years of age. This type of hypertension is related to loss of arterial elasticity. Another factor is a rising probability of incidence of other diseases. Therefore, we use cardioprotective drugs with no negative effects on associated diseases. Blood pressure lowering decreases both cardiovascular and total risk.

Keywords: Key words: arterial hypertension, treatment, elderly.

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Seidlerová J, Filipovský J. TREATMENT OF ARTERIAL HYPERTENSION IN THE ELDERLY. Interní Med. 2007;9(2):75-77.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosine vs chlorthalidone. JAMA 2000; 283: 1967-1975. Go to original source...
    2. Cífková R, Škodová Z, Lánská V, Adámková V, Novozámská E, Jozifová M, Plasková M, Hejl Z, Petržilková Z, Galovcová M, Palous D: Prevalence, awareness, treatment, and control of hypertension in the Czech Republic. Results of two nationwide cross-sectional surveys in 1997/1998 and 2000/2001, Czech Post-MONICA Study. J Hum Hypertens. 2004;18: 571-579. Go to original source... Go to PubMed...
    3. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen M, Omvik P, Oparil S, Wedel H, LIFE study group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1010. Go to original source... Go to PubMed...
    4. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR. Babeanu S et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 2002; 162: 2046-2052. Go to original source... Go to PubMed...
    5. Gottlieb SS, McCarter RJ, Vogel RA, M.D. effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. NEJM. 1998; 339: 489-497. Go to original source... Go to PubMed...
    6. Julius S, Kjeldsen S, Weber M, Brunner H, Ekman S, Hansson L, Hua T, Laragh J, McInnes G, Mitchell L: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031. Go to original source... Go to PubMed...
    7. Kaplan NM: Kaplan's Clinical Hypertension. Ninth Edition. Philadelphia, USA: Lippincott Williams & Wilkins 2006.
    8. Lithell H, Hansson L, Skoog I. The study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886. Go to original source... Go to PubMed...
    9. Pickering TG: Treatment of hypertension in the elderly. J Clin Hypertens 2004; 6 (10 Suppl 2): 18-23. Go to original source... Go to PubMed...
    10. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekborn T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Tabard RH: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-872. Go to original source... Go to PubMed...
    11. Souček M, Kára T et al: Klinická patofyziologie hypertenze. Praha: Grada Publishing 2002.
    12. Soucek M, Widimsky J, Lanska V: Control of hypertension in patiens with hypertension, diabetes, and impaired fasting glukose by Czech primary care physicians. Kidney Blood Press Res 2006; 29: 366-372. Go to original source... Go to PubMed...
    13. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch W, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney International 2004; 65: 2309-2320. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.